Showing results (121-130 of 132) with videos related to
Sort By:
Pageof 14
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 25, 2025
External Validation of the GOLDEN Model for Predicting HBsAg Loss in Noncirrhotic Chronic Hepatitis B Patients With Interferon-Alpha-Based TherapyXingmei Liao, Qing Xie, Xiaoguang Dou, et al.Journal of Clinical and Translational Hepatology|July 5, 2021
3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in ChinaJinlin Hou, Qin Ning, Zhongping Duan, et al.Journal of Gastroenterology and Hepatology|March 23, 2016
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirinLai Wei, Mingxiang Zhang, Min Xu, et al.Journal of Clinical and Translational Hepatology|May 23, 2024
Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B PatientsJinlin Hou, Qin Ning, Zhongping Duan, et al.Journal of Clinical and Translational Hepatology|October 15, 2019
Efficacy and Safety of 12-week Interferon-based Danoprevir Regimen in Patients with Genotype 1 Chronic Hepatitis CLai Wei, Jia Shang, Yuanji Ma, et al.Journal of Clinical and Translational Hepatology|March 11, 2026
Eight-year Results from Two Randomized Phase 3 Trials of Tenofovir Alafenamide for Chronic Hepatitis B Virus Infection in ChinaJinlin Hou, Qin Ning, Zhongping Duan, et al.Expert Opinion on Biological Therapy|August 1, 2018
Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label studyXiaoning Wu, Yiwen Shi, Jialing Zhou, et al.Hepatology International|October 31, 2020
Entecavir combining Chinese herbal medicine for HBeAg-positive chronic hepatitis B patients: a randomized, controlled trialXiaoke Li, Daqiao Zhou, Xiaoling Chi, et al.International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 30, 2020
Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeksXiaomei Wang, Zhongfeng Wang, Xiumei Chi, et al.Trials|August 14, 2020
Chinese herbal medicine combined with entecavir to reduce the off-therapy recurrence risk in HBeAg-positive chronic hepatitis B patients: a multicener, double-blind, randomized controlled trial in ChinaXiaoke Li, Ludan Zhang, Mei Qiu, et al.Pageof 14